2-溴-4-(1-哌啶甲基)吡啶 | 88046-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-溴-4-(1-哌啶甲基)吡啶
• 中文别名: 2-溴-4-[(哌啶-1-基)甲基]吡啶；2-溴-4-(哌啶甲基)吡啶
• 英文名称: 2-bromo-4-(1-piperidinomethyl)pyridine
• 英文别名: 2-bromo-4-(piperidinomethyl)pyridine；2-bromo-4-(piperidin-1-ylmethyl)pyridine
• CAS: 88046-02-0
• 化学式: C₁₁H₁₅BrN₂
• 分子量: 255.157
• InChiKey: ZTUBSWOWTOUXJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  331℃
• 密度：
  1.377
• 闪点：
  154℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-溴-4-(1-哌啶甲基)吡啶 生成 4-(4-piperidinomethyl-2-pyridyloxy)-cis-2-butenylamine
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  哌啶 、 2-溴吡啶-4-甲醛 生成 2-溴-4-(1-哌啶甲基)吡啶
  参考文献：
  名称：

  Dual serotonin transporter inhibitor/histamine H3 antagonists: Development of rigidified H3 pharmacophores

  摘要：

  A series of tetrahydroisoquinolines acting as dual serotonin transporter inhibitor/histamine H-3 antagonists is described. The introduction of polar aromatic spacers as part of the histamine H-3 pharmacophore was explored. A convergent synthesis of the final products allowing late stage introduction of the aromatic side chain was developed. In vitro and in vivo data are discussed. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.017

文献信息

• 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES
  申请人：van der Stelt Marcelis

  公开号：US20100144724A1

  公开（公告）日：2010-06-10

  The invention relates to 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivative having the general Formula I wherein R 1 is H, (C 1-6 )alkyl (optionally substituted with oxo, (C 1-3 )alkyloxy, (C 1-3 )alkyloxycarbonyl, halogen or CN), (C 3-6 )cycloalkyl or (C 3-6 )cycloalkyl(C 1-3 )alkyl, each cycloalkyl ring optionally comprising a heteroatom selected from O and S; R 2 and R 3 are independently H or (C 1-3 )alkyl; or R 2 and R 3 form together with the carbon atom to which they are bound a (C 3-5 )cycloalkyl group; R 4 is H or 1 to 3 F substituents; R 5 is H or 1 to 4 F substituents; R 6 and R 7 are independently H or F; X represents R 8 , OR 8 , NR 8 R 9 , R 8 is (C 5-7 )cycloalkyl optionally comprising a heteroatom selected from O, S, SO and SO 2 ; R 9 is H or (C 1-4 )alkyl; R 10 represents 1-3 substituents independently selected from H, (C 1-3 )alkyl, halogen, oxo, CN and CF 3 ; Y is CF 2 , O, S, SO or SO 2 ; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.

  该发明涉及具有一般式I的1-(4-(吡啶-2-基)苄基)咪唑啉二酮衍生物，其中R1为H，(C1-6)烷基（可选择地取代为氧代、(C1-3)烷氧基、(C1-3)烷氧羰基、卤素或CN），(C3-6)环烷基或(C3-6)环烷基(C1-3)烷基，每个环烷基环可选择包含从O和S中选择的杂原子; R2和R3分别为H或(C1-3)烷基; 或R2和R3与它们连接的碳原子一起形成(C3-5)环烷基基团; R4为H或1至3个F取代基; R5为H或1至4个F取代基; R6和R7分别为H或F; X代表R8，OR8，NR8R9，R8为(C5-7)环烷基，可选择包含从O、S、SO和SO2中选择的杂原子; R9为H或(C1-4)烷基; R10代表1-3个取代基，独立选择自H、(C1-3)烷基、卤素、氧代、CN和CF3; Y为CF2、O、S、SO或SO2;或其药学上可接受的盐，以及包含该类化合物的药物组合物，以及所述1-(4-(吡啶-2-基)苄基)咪唑啉二酮衍生物在治疗疼痛中的用途，例如围手术期疼痛、慢性疼痛、神经性疼痛、癌症疼痛以及与多发性硬化相关的疼痛和痉挛。
• 4-aminomethyl-pyridyl-2-oxy derivatives having anti-ulcer activity
  申请人：Fujirebio Kabushiki Kaisha

  公开号：US04912101A1

  公开（公告）日：1990-03-27

  A compound represented by the following formula or a salt thereof ##STR1## wherein each of R.sub.1 and R.sub.2 represents a lower alkyl group, or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, may form a substituted or unsubstituted, saturated or partially unsaturated 4- to 8-membered heterocyclic group which may contain a hetero atom selected from N, O and S, Y represents a group of the formula --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2. This compound is useful as anti-peptic ulcer agent.

  该化合物由以下式表示，或其盐##STR1##其中R.sub.1和R.sub.2中的每一个代表较低的烷基基团，或者R.sub.1和R.sub.2，与它们结合的氮原子一起，可以形成一个取代或未取代、饱和或部分不饱和的4-至8-成员杂环基团，该基团可能包含从N、O和S中选择的杂原子，Y代表式--CH.sub.2 --CH.sub.2 --或--CH.dbd.CH--的基团，n为0、1或2。该化合物可用作抗溃疡药。
• Intermediates for pyridyloxy compounds having utility as anti-peptic
  申请人：Fujirebio Kabushiki Kaisha

  公开号：US04977267A1

  公开（公告）日：1990-12-11

  The compounds of the formulas (VI) and (VII) are useful intermediates in producing pyridyloxy derivatives of the formula (I), such as, for instance, N-4-[4-(piperidinomethyl)pyridyl-2-oxy]-2-butenyl}-2-(furfurylt hio)acetamide, which are useful as anti-peptic ulcer agents. The compounds of formula (VI) have the formula ##STR1## wherein A represents a formyl group, a protected formyl group, a hydroxymethyl group or a protected hydroxymethyl group. The compounds of formula (VIII) have the formula ##STR2## wherein G represents a formyl group, a protected formyl group, a hydroxymethyl group, a hydroxymethyl group in which the hydroxyl group is protected, or a halogenomethyl group, Y represents --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2.

  公式（VI）和（VII）的化合物是制备公式（I）的吡啶氧衍生物的有用中间体，例如，N-4-[4-(哌啶甲基)吡啶-2-氧基]-2-丁烯基}-2-(呋喃甲硫基)乙酰胺，其作为抗消化性溃疡剂很有用。 公式（VI）的化合物具有以下公式##STR1##其中A代表甲酰基，受保护的甲酰基，羟甲基或受保护的羟甲基。公式（VIII）的化合物具有以下公式##STR2##其中G代表甲酰基，受保护的甲酰基，羟甲基，受保护羟甲基，或卤代甲基，Y代表--CH.sub.2 --CH.sub.2 --或--CH.dbd.CH--，n为0、1或2。
• DIARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AS HISTAMINE H3 RECEPTOR AND SEROTONIN TRANSPORTER MODULATORS
  申请人：Keith John M.

  公开号：US20080318952A1

  公开（公告）日：2008-12-25

  Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H 3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H 3 receptor- and/or serotonin-mediated diseases.

  某些二芳基取代的四氢异喹啉化合物是组胺H3受体和/或血清素转运体调节剂，可用于治疗组胺H3受体和/或血清素介导的疾病。
• Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US07846930B2

  公开（公告）日：2010-12-07

  Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.

  某些二芳基取代的四氢异喹啉化合物是组胺H3受体和/或血清素转运体调节剂，可用于治疗组胺H3受体和/或血清素介导的疾病。